Logo-ajmb
Submitted: 20 Apr 2024
Revision: 13 May 2024
Accepted: 14 May 2024
ePublished: 30 Jun 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Avicenna J Med Biochem. 2024;12(1): 39-46.
doi: 10.34172/ajmb.2527
  Abstract View: 242
  PDF Download: 235

Review Article

Emerging Therapeutics Targeting Cellular Stress Pathways to Mitigate End-Organ Damage in Type 1 Diabetes

Tamer A. Addissouky 1,2,3* ORCID logo

1 Medical Laboratories Techniques Department, AL-Mustaqbal University College, 51001, Hillah, Babil, Iraq
2 New Burg El-Arab Hospital, Ministry of Health, Alexandria, Egypt
3 Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt
*Corresponding Author: Tamer A. Addissouky, Email: tedesoky@science.menofia.edu.eg, Email: tedesoky@gmail.com

Abstract

Type 1 diabetes (T1D) is an autoimmune disease characterized by insulin deficiency and impaired glucose regulation. While daily insulin therapy is life-saving, many patients struggle to achieve optimal glycemic control, leading to microvascular complications affecting various organs, including the kidneys and the liver. This review aims to summarize the current state of knowledge regarding the pathogenesis of hepatic and renal complications in T1D, highlight recent advances in potential therapeutic targets, and provide evidence-based recommendations for mitigating end-organ damage. Chronic hyperglycemia drives diabetic complications through several interrelated mechanisms, including increased polyol pathway flux, advanced glycation end-product (AGE) formation, protein kinase C activation, and mitochondrial reactive oxygen species overproduction. In the liver, these processes contribute to non-alcoholic fatty liver disease, with up to 50% of T1D patients developing hepatic steatosis. Diabetic nephropathy, affecting 25%–40% of long-term T1D patients, is characterized by glomerular basement membrane thickening, mesangial expansion, and tubulointerstitial fibrosis. Recent innovations in T1D management include genomics and precision medicine approaches, gut microbiome modulation, nanomedicine, and artificial intelligence-driven glucose monitoring systems. Emerging immunotherapies aim to fundamentally modify the autoimmune response in T1D. Mitigating T1D complications requires intensive glycemic control, targeted pharmacotherapy, and lifestyle modifications. Emerging therapies and precision medicine approaches offer promising avenues. Ongoing research into molecular mechanisms remains crucial for developing novel interventions and improving long-term outcomes in T1D patients.

Please cite this article as follows: Addissouky TA. Emerging therapeutics targeting cellular stress pathways to mitigate end-organ damage in type 1 diabetes. Avicenna J Med Biochem. 2024; 12(1):39-46. doi:10.34172/ajmb.2527
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 243

Your browser does not support the canvas element.


PDF Download: 235

Your browser does not support the canvas element.